Document Detail

Disease-modifying antirheumatic drugs increase serum adiponectin levels in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  21169855     Owner:  NLM     Status:  In-Process    
BACKGROUND: Adiponectin is an adipocyte-derived adipokine with immunosuppressive and anti-inflammatory properties. It also decreases expression of adhesion molecules. In terms of its relationship with acute-phase reactants, there are conflicting results in patients with rheumatoid arthritis (RA).
OBJECTIVES: The objectives of this study were to evaluate the levels of adiponectin in RA patients before and after the treatment with disease-modifying antirheumatic drugs (DMARDs) and to evaluate whether there is a correlation between adiponectin levels and disease activity and acute-phase-response reactants (APRRs).
METHODS: Serum adiponectin levels, APRRs, total and high-density lipoprotein cholesterol (HDL-C), body mass index, and body fat mass were measured in 27 patients with RA before and after the treatment with DMARDs plus prednisolone. An inclusion criterion for RA patients was to be DMARD naive for at least 6 months or to have been newly diagnosed with RA. Twenty patients with osteoarthritis were included in this study as a disease control.
RESULTS: No significant difference was found between RA and osteoarthritis group in terms of baseline adiponectin level. Mean adiponectin level and mean HDL-C level increased significantly compared with mean baseline level after the treatment with DMARDs plus prednisolone (10 [SD, 4.9] vs. 13.9 [SD, 8.7] μg/mL; P < 0.001; 56.8 [SD, 19] vs. 65 [SD, 18] mg/dL, P < 0.004, respectively). APRRs and the 28-joint-count disease activity score decreased significantly at the end of the 3 months of therapy. The adiponectin levels tended to be negatively correlated with acute-phase reactants and disease activity, although no changes were significant. There was a positive correlation between HDL-C and adiponectin levels at 3 month (r = 0.53, P < 0.001). No correlation was found between erythrocyte sedimentation rate and adiponectin levels both at baseline and at 3 months.
CONCLUSION: Adiponectin levels can be modified by effective treatment of rheumatoid arthritis. This suggests that active inflammation may decrease serum adiponectin levels. In consideration of the antiatherogenic and anti-inflammatory features of adiponectin, increased adiponectin levels in patients with RA may result in a more favorable cardiovascular profile.
Barş Cansu; Döndü U Cansu; Timuçin Kaşifoğlu; Zafer Gülbas; Cengiz Korkmaz
Related Documents :
3451215 - Coagulation abnormalities in patients with eosinophilia.
21229375 - Disease activity score 28 may overestimate the remission induction of rheumatoid arthri...
21325965 - Protracted rheumatic manifestations in travelers.
15916295 - Treatment of an acquired coagulopathy with recombinant activated factor vii in a damage...
10436335 - Comparative cognitive neuropsychological studies of frontal lobe function: implications...
17367215 - Childhood-onset multiple sclerosis: report of 82 patients from isfahan, iran.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases     Volume:  17     ISSN:  1536-7355     ISO Abbreviation:  J Clin Rheumatol     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9518034     Medline TA:  J Clin Rheumatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  14-7     Citation Subset:  IM    
Department of Internal Medicine, Division of Rheumatology, Eskişehir Osmangazi University, Eskişehir, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence of subclinical enthesopathy in patients with spondyloarthropathy: an ultrasound study.
Next Document:  Renal function in gout: long-term treatment effects of febuxostat.